Long before immunotherapy took center stage, it lived on the margins of oncology. Those pursuing it were often politely dismissed as “dreamers,” relegated to the back rooms at ASCO as well-intentioned, but unrealistic in their belief that the immune system could be trained to fight cancer. Rather than abandon the idea, they chose to stay on the path less travelled. This panel brings together members of that original community of quiet architects who helped turn scientific curiosity into a life-extending standard of care. Their conversation will reflect on the moments of uncertainty, the small signals that kept them moving forward, and the collaborations that gave early observations room to grow. Lastly, panelists will explore the future they envision - new immune pathways, next-generation combinations, and emerging tools that may help uncover deeper and more durable responses.